Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ascendis Pharma A (ASND) EBITDA Margin: 2014-2025

Historic EBITDA Margin for Ascendis Pharma A (ASND) over the last 12 years, with Sep 2025 value amounting to -0.74%.

  • Ascendis Pharma A's EBITDA Margin fell 100.00% to -0.74% in Q3 2025 from the same period last year, while for Sep 2025 it was -6.07%, marking a year-over-year increase of 2068.00%. This contributed to the annual value of -103.68% for FY2024, which is 7785.00% up from last year.
  • According to the latest figures from Q3 2025, Ascendis Pharma A's EBITDA Margin is -0.74%, which was up 16.77% from -0.89% recorded in Q2 2025.
  • Ascendis Pharma A's 5-year EBITDA Margin high stood at 1.19% for Q3 2023, and its period low was -13,140.61% during Q2 2021.
  • In the last 3 years, Ascendis Pharma A's EBITDA Margin had a median value of -0.74% in 2025 and averaged -8.22%.
  • Within the past 5 years, the most significant YoY rise in Ascendis Pharma A's EBITDA Margin was 2,381,327bps (2021), while the steepest drop was 651,951bps (2021).
  • Ascendis Pharma A's EBITDA Margin (Quarterly) stood at -2,143.92% in 2021, then surged by 124,762bps to -896.30% in 2022, then spiked by 83,212bps to -64.18% in 2023, then spiked by 4,254bps to -21.64% in 2024, then tumbled by 100bps to -0.74% in 2025.
  • Its EBITDA Margin stands at -0.74% for Q3 2025, versus -0.89% for Q2 2025 and -0.07% for Q1 2025.